• Link to Facebook
  • Link to X
  • Link to Youtube
  • Link to LinkedIn
  • Contact
We support stroke randomised trials in Europe
ESOTA — ESO Trials Alliance
  • About
    • ESOTA
    • ESO
    • ESO Trials Network Committee
    • Criteria for Membership
  • Member Networks
  • Education
    • Seminars
    • Support materials
  • Resources
    • Ongoing Trials in Europe
    • Trial Regulations
    • International Funding Agencies
  • Publications
  • Blog
  • Menu Menu

Ongoing ESOTA Trials

The aim of the Trials Network Committee is to facilitate academic clinical stroke research in Europe.

Within the networks various trials are actively recruiting. We would like to refer to the ‘Member Networks’ page to find more information about clinical studies within each network. Below you can find a link to clinicaltrials.gov which contains an overview of clinical stroke trials in all European countries.

Infortmation concerning funding and insurance can be found here.

Investigators will find the following resources:

1.

Database of ongoing stroke research: A repository of > 100 ongoing clinical stroke studies running in two or more European countries, including information about the coordinating investigators behind these trials. [click here]

2.

An overview of relevant courses and other resources organised and provided by each network can be found on the webpages of the national networks. [click here]

Existing trials collaborating with ESOTA networks

AMASCIS (Autologous Mesenchymal Stem Cells in Ischaemic Stroke)

Principal Investigator: Prof Exuperio Díez Tejedor

AMASCIS investigates the safety and feasibility of using autologous mesenchymal stem cells in patients with ischaemic stroke. This early-phase study explores the potential for regenerative therapies in stroke recovery.

Status: Ongoing
ClinicalTrials.gov ID: NCT01678534

BIRCH (A study to evaluate the safety, tolerability and the effects of Ixodes ricinus-Contact Phase Inhibitor (Ir-CPI) in adult patients with spontaneous intracerebral haemorrhage))

Principal Investigator: Belgium-based study

A study to evaluate the safety, tolerability and the effects of Ixodes ricinus-Contact Phase Inhibitor (Ir-CPI) in adult patients with spontaneous intracerebral haemorrhage.

Status: Ongoing
https://euclinicaltrials.eu/ctis-public/view/2022-500491-53-00ClinicalTrials.gov ID: NCT05970224

BRIGHT (Phase IIb Study of LT3001 in Acute Ischemic Stroke)

Principal Investigator: Dr. Thomas Devlin

The BRIGHT study is a multinational, randomized, double-blind, placebo-controlled Phase IIb clinical trial evaluating the safety and efficacy of multiple doses of LT3001 (odatroltide) in patients with acute ischemic stroke (AIS) who are not eligible for thrombolysis or mechanical thrombectomy. LT3001 is a novel small synthetic peptide designed to restore cerebral blood flow and reduce reperfusion injury.

The trial plans to enroll approximately 200 participants across multiple countries, including the United States, Taiwan, and Greece.​

Status: Recruiting (as of March 2025)
ClinicalTrials.gov ID: NCT05403866

CASES (Carotid Artery Stenting during Endovascular Treatment of Acute Ischemic Stroke versus Deferred Stenting)

Principal Investigator:  Prof Dr M Uyttenboogaart / Belgium-based study

CASES is a multicentre trial investigating the benefits and risks of immediate versus deferred carotid artery stenting in patients undergoing endovascular treatment for acute ischaemic stroke. The trial aims to optimise stroke care by informing procedural timing for carotid intervention.

Status: Ongoing
More information

CHOICE-2 (Intra-arterial Administration of Alteplase After Thrombectomy)

Principal Investigator: Dr Angel Chamorro

CHOICE-2 builds upon earlier studies by evaluating intra-arterial alteplase administration immediately following thrombectomy. The goal is to enhance recanalisation quality and improve clinical outcomes in acute ischaemic stroke.

Status: Ongoing
ClinicalTrials.gov ID: NCT03876119

DIST (Dutch ICH Surgery Trial)

PI: Prof. Dr. Karin Klijn, Radboud University Medical Center – The Netherlands

DO-IT (Thrombolysis in patients treated with NOACS)

PI: Dr Thomas Meinel, University of Bern – Switzerland

https://clinicaltrials.gov/study/NCT06571149

ELAPSE (Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy)

Principal Investigator: Prof. Lorenz Räber

The ELAPSE study investigates early closure of the left atrial appendage as a preventive strategy in atrial fibrillation patients who suffer an ischaemic stroke despite anticoagulation. The trial focuses on reducing recurrence rates and improving long-term outcomes.

Status: Ongoing
ClinicalTrials.gov ID: NCT05976685

ENRICH-AF (EdoxabaN for IntraCranial Hemorrhage Survivors with Atrial Fibrillation)

Principal Investigator: Dr. Ashkan Shoamanesh

ENRICH-AF is an international, Phase 4, randomized, open-label, blinded-endpoint (PROBE) clinical trial evaluating the efficacy and safety of edoxaban in patients with atrial fibrillation (AF) who have survived an intracranial hemorrhage (ICH). The study aims to determine whether edoxaban reduces the risk of stroke or systemic embolism compared to standard medical therapy (no antithrombotic therapy or antiplatelet monotherapy) in this high-risk population.​

The trial plans to enroll approximately 1,380 participants across 238 sites in 20 countries, including 14 European countries.​

Status: Active, not recruiting (as of January 2025)
ClinicalTrials.gov ID: NCT03950076

FibER (Fibrinogen Replacement to Prevent Intracranial Haemorrhage in Ischaemic Stroke Patients After Thrombolysis)

Principal Investigator: Italy-based study

FibER is a pilot randomised controlled trial evaluating whether fibrinogen replacement can prevent intracranial haemorrhage in ischaemic stroke patients following thrombolysis. The trial will help define future protocols for haemorrhage prevention.

Status: Ongoing
ClinicalTrials.gov ID: NCT0530067
EudraCT Number: 2020-005242-41 

HOPE (Haemorrhagic transformation risk Prediction and prevention in ischaemic stroke)

Principal Investigator: Dr Joan Martí Fàbregas

HOPE aims to better understand the risk of haemorrhagic transformation following ischaemic stroke and identify effective prevention strategies. The study integrates clinical, imaging, and biomarker data.

Status: Ongoing
ClinicalTrials.gov ID: NCT04892511

PhEAST-3 (Pharyngeal electrical stimulation for dysphagia after stroke)

PI: Professor Philip M Bath, University of Nottingham – UK
ethics applications are underway; aim for first patient is Oct/Nov 2023 (Status: August 2023)

REvive (A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke)

REvive is a multinational, Phase 2b, randomized, double-blind clinical trial evaluating the efficacy and safety of redasemtide (S-005151) in adult patients with acute ischemic stroke (AIS) who are not eligible for thrombolysis or mechanical thrombectomy. The study aims to determine whether redasemtide can improve functional outcomes in this patient population.

The trial plans to enroll approximately 627 participants across multiple countries, including Australia, Belgium, China, Czechia, Denmark, Finland, Germany, Greece, and other.

Status: Recruiting (as of March 2025)
ClinicalTrials.gov ID: NCT05953480

TICH-3

PI: Prof Nikola Sprigg, U Nottingham – UK
Tranexamic acid vs placebo for acute non-traumatic ICH <4.5 hours onset Overall 392 participants UK 306 participants have been recruited. 56 UK sites are opened and 52 of these have recruited. For TICH-3 International, 82 participants have been recruited and there are 19 sites opened: Malaysia: 13, Georgia:3, Denmark: 1, Finland:1, Italy:1 Out of the 19 sites, 14 have recruited. Recruitment open in Italy, Denmark, Finland. Sites to pen in  Ireland, Spain, France, Swizerland soon. Additional countries sites welcome only if able to secure funding locally. New sites/investigators contact tich-3@nottingham.ac.uk

TECNO (Safety and Efficacy of intra-arterial Tenecteplase for non-complete reperfusion of intracranial occlusions)

PI: Steering Committee

TECNO is a multicenter, prospective, randomized, open label, blinded endpoint (PROBE) trial utilizing an adaptive statistical design comparing the rates of early and late reperfusion in patients with incomplete mechanical thrombectomy treated either by IA TNK or by best medical treatment BMT. This trial has two balanced treatment arms, with the IA TNK being the experimental arm. The standard arm is defined as BMT after incomplete MT. 156 patients will be randomly assigned to either the standard or the experimental arm with a ratio of 1:1 (78 patients per group).

About The Trial

Trials in planning phase collaborating with ESOTA networks

ASPIRING (Antiplatelet Secondary Prevention International Randomised trial after Intracerebral haemorrhage)

PI: Prof Rustam al-Shahi Salman, University of Edinburg – UK

The Antiplatelet Secondary Prevention International Randomised trial after INtracerebral haemorrhaGe (ASPIRING) is funded to start in 2024 in the UK, Canada, The Netherlands, and Australia with funding via the GCRFF Multinational Clinical Trials initiative from the British Heart Foundation, Canadian Institutes of Health Research, Dutch Heart Foundation, and National Health and Medical Research Council Medical Research Future Fund respectively.

(Status August 2023)

European blood pressure intensive control after stroke – pilot trial (EPICS-Pilot)

PI: Prof Peter Kelly, University College Dublin – Ireland
ethics applications are underway; aim for first patient is Oct/Nov 2023 (Status: August 2023)

Additional ongoing stroke randomised trials in Europe

Visit ClinicalTrials.gov

Other European networks and GAINS


BeNET – Belgian Network for Clinical Stroke Trials


Czech Stroke Research Network – STROCZECH


French StrokeLink


HRB Stroke Clinical Trials Network Ireland


Hellenic Society of Cerebrovascular Diseases Clinical Trial Network (HSCVDCTN)


Italian Stroke Research Network


UK Stroke Clinical research network


Netherland CONTRAST network


Scottish Stroke Research Network


Spanish Neurological Society


Stroke Trials Network Germany


Swiss Stroke Network


TurkStrokeNet – Turkish Stroke Research and Clinical Trials Network


European Clinical Research Infrastructure Network


GAINS

European Stroke Organisation
Reinacherstrasse 131
4053 Basel / Switzerland
E: esoinfo@eso-stroke.org

 

 

© ESO-TRIALSALLIANCE
  • Link to Facebook
  • Link to X
  • Link to Youtube
  • Link to LinkedIn
  • Imprint
  • Privacy Statement
  • Disclaimer
  • Contact
Scroll to top Scroll to top Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept SettingsSettings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Statement
Accept settingsHide notification only
Open Message Bar Open Message Bar Open Message Bar